Preliminary identification of CD4 T cell epitopes in genotype 1 and 6 of hepatitis C virus
10.13303/j.cjbt.issn.1004-549x.2022.07.003
- VernacularTitle:基因1型和6型HCV CD4 T细胞抗原表位的初步鉴定
- Author:
Jieting HUANG
1
;
Qingzhu YOU
2
;
Fengpei LI
1
;
Ru XU
1
;
Min WANG
1
;
Qiao LIAO
1
;
Zhengang SHAN
1
;
Xia RONG
1
;
Yongshui FU
1
Author Information
1. Guangzhou Blood Center, Guangzhou Key Laboratory of Blood Safety, Guangzhou 510095, China
2. Department of Otolaryngology, Shaoguan First People′s Hospital
- Publication Type:Journal Article
- Keywords:
hepatitis C virus;
genotype;
CD4 T cell epitope;
vaccine;
blood donor
- From:
Chinese Journal of Blood Transfusion
2022;35(7):693-697
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To study the CD4 T cell epitopes in Core and NS3 protein of genotype 1(GT1) and 6(GT6) of hepatitis C virus(HCV). 【Methods】 A total of 298 overlapping peptides(16-mer) spanning Core and NS3 protein of GT1 and GT6 HCV were synthesized. Peripheral blood mononuclear cells(PBMCs) from 17 HCV+ and 7 healthy blood donors were stimulated by peptide pools, followed by evaluating T cell response by IFN-γ ELISPOT, by which 21 peptides with positive results were found. These peptides were further applied to individually stimulate 20 HCV+ and 18 healthy PBMCs. The differences of responsive frequencies to the 21 positive peptides between the two study groups were compared. 【Results】 Pooled and individual peptide stimulation tests showed that HCV+ PBMCs were responsive to the stimulation of 5 peptides(GT1 NS31273-1288 and NS31315-1330; GT6 NS31033-1048, NS31087-1102 and NS31351-1366), with a responsive frequency ranging 18.9%-27.0%. In contrast, healthy PBMCs were not or low responsive(0%-4.0%) to these five peptides. The responsive frequencies were statistically different between the two groups(P<0.05). No reported epitopes in IEDB were found identical with these 5 peptides via sequence alignment. 【Conclusion】 Our study identified novel CD4 T cell epitopes in NS3 protein of GT1 and GT6 HCV, which has potential application value for the research and development of HCV vaccine.
